Vanguard Group Inc Alkermes Plc. Call Options Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALKS
# of Institutions
408Shares Held
176MCall Options Held
229KPut Options Held
436K-
Black Rock Inc. New York, NY29.1MShares$773 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.8MShares$313 Million0.05% of portfolio
-
State Street Corp Boston, MA8.02MShares$213 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.88MShares$183 Million3.72% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny5.74MShares$152 Million0.3% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.36B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...